P. Ravdin

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

P. Ravdin, Howard A. Burris, Gary Cook et al. · Journal of Clinical Oncology · 1995 · 319 citations

Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.

P. Ravdin, Nancy F. Fritz, D C Tormey et al. · PubMed · 1988 · 122 citations

Hormonal Contraceptive, Long-term Tamoxifen, Breast Oncology +15

Accumulation of p53 Protein as a Possible Predictor of Response to Adjuvant Combination Chemotherapy With Cyclophosphamide, Methotrexate, Fluorouracil, and Prednisone for Breast Cancer

Richard Elledge, Robert J. Gray, Edward G. Mansour et al. · JNCI Journal of the National Cancer Institute · 1995 · 98 citations

Breast Oncology, Pathology, P53 Protein +16

Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).

Daniel R. Ciocca, S Green, Richard Elledge et al. · PubMed · 1998 · 45 citations

Breast Oncology, Immunology, Pathology +16

Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).

Kathy S. Albain, William Barlow, S. Shak et al. · Cancer Research · 2009 · 16 citations

Breast Oncology, Pathology, Superior Bcss +16